Association of Treatment with Metformin vs Sulfonylurea with Major Adverse Cardiovascular Events Among Patients with Diabetes and Reduced Kidney Function
Roumie CL, Chipman J, Min JY, et al
JAMA. Pub online 19 September 2019
Leggi
Breaking news
Use of Fenofibrate On Cardiovascular Outcomes in Statin Users with Metabolic Syndrome: Propensity Matched Cohort Study
Kim NH, Han KH, Choi J, et al.
BMJ 2019;366 :l5125
Leggi
Sulfonylureas and Cardiovascular Safety – The Final Verdict?
Wexler DJ
JAMA. 2019;322(12):1147-49
Leggi
Cardiovascular Corner – Prescription Omega-3s, Stroke Rehab, and Statins After Age 75
Abbasi J
JAMA. Pub. online 11 September 2019
Leggi
Lipid-Lowering Prescription Patterns in Patients with Diabetes Mellitus or Cardiovascular Disease
Chamberlain AM, Cohen SS, Killian JM, et al.
Am J Cardiol. 2019;124(7):995-1001
Leggi
What should governments be doing to prevent diabetes throughout the life course?
Timpel P, Harst L, Reifegerste D, et al.
Diabetologia. 2019,62:1842-53
Leggi
Association of Metabolic Surgery with Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes and Obesity
Aminian A, Zajichek A,Arterburn DE, et al.
JAMA. Pub. online 2 September 2019
Leggi
Trends in Incidence of Total or Type 2 Diabetes: Systematic Review
Magliano DJ, Islam RM, Barr ELM, et al.
BMJ 2019;366:l5003
Leggi
Environmental neglect: endocrine disruptors as underappreciated but potentially modifiable diabetes risk factors
Sargis RM, Simmons RA
Diabetologia. 2019,62:1811-22
Leggi
Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course
Huebschmann AG, Huxley RR, Kohrt WM, et al.
Diabetologia. 2019, 62:1761–1772
Leggi